Free Trial

Armata Pharmaceuticals Q2 2024 Earnings Report

Armata Pharmaceuticals logo
$1.95 -0.03 (-1.52%)
(As of 12/20/2024 04:32 PM ET)

Armata Pharmaceuticals EPS Results

Actual EPS
-$0.65
Consensus EPS
-$0.52
Beat/Miss
Missed by -$0.13
One Year Ago EPS
N/A

Armata Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Armata Pharmaceuticals Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Armata Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Armata Pharmaceuticals and other key companies, straight to your email.

About Armata Pharmaceuticals

Armata Pharmaceuticals (NYSEAMERICAN:ARMP), a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.

View Armata Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Upcoming Earnings